AIM:IDH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Immunodiagnostic Systems Holdings

Executive Summary

Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has Immunodiagnostic Systems Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IDH is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: IDH's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

-14.0%

IDH

3.4%

GB Medical Equipment

3.0%

GB Market


1 Year Return

-21.2%

IDH

-3.5%

GB Medical Equipment

-6.1%

GB Market

Return vs Industry: IDH underperformed the UK Medical Equipment industry which returned -5% over the past year.

Return vs Market: IDH underperformed the UK Market which returned -5.6% over the past year.


Shareholder returns

IDHIndustryMarket
7 Day-14.0%3.4%3.0%
30 Day10.3%7.1%11.1%
90 Day2.4%4.8%11.9%
1 Year-20.6%-21.2%-1.6%-3.5%-2.4%-6.1%
3 Year-20.4%-21.8%18.2%11.4%4.5%-8.2%
5 Year-12.2%-15.7%49.9%37.8%38.9%7.4%

Long-Term Price Volatility Vs. Market

How volatile is Immunodiagnostic Systems Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Immunodiagnostic Systems Holdings undervalued compared to its fair value and its price relative to the market?

162.87x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: IDH (£2.15) is trading above our estimate of fair value (£0.32)

Significantly Below Fair Value: IDH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: IDH is poor value based on its PE Ratio (162.9x) compared to the GB Medical Equipment industry average (43.1x).

PE vs Market: IDH is poor value based on its PE Ratio (162.9x) compared to the UK market (21.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IDH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IDH is good value based on its PB Ratio (1.1x) compared to the GB Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is Immunodiagnostic Systems Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

25.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunodiagnostic Systems Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Immunodiagnostic Systems Holdings performed over the past 5 years?

66.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IDH has a large one-off gain of £670.0K impacting its September 30 2020 financial results.

Growing Profit Margin: IDH's current net profit margins (1.1%) are lower than last year (2.9%).


Past Earnings Growth Analysis

Earnings Trend: IDH has become profitable over the past 5 years, growing earnings by 66.3% per year.

Accelerating Growth: IDH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: IDH had negative earnings growth (-66.3%) over the past year, making it difficult to compare to the Medical Equipment industry average (-36.8%).


Return on Equity

High ROE: IDH's Return on Equity (0.7%) is considered low.


Next Steps

Financial Health

How is Immunodiagnostic Systems Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IDH's short term assets (£46.5M) exceed its short term liabilities (£8.6M).

Long Term Liabilities: IDH's short term assets (£46.5M) exceed its long term liabilities (£5.2M).


Debt to Equity History and Analysis

Debt Level: IDH is debt free.

Reducing Debt: IDH currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: IDH has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IDH has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Immunodiagnostic Systems Holdings's current dividend yield, its reliability and sustainability?

0.88%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: IDH's dividend (0.88%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.67%).

High Dividend: IDH's dividend (0.88%) is low compared to the top 25% of dividend payers in the UK market (4.79%).


Stability and Growth of Payments

Stable Dividend: IDH is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.

Growing Dividend: IDH is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: IDH is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IDH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.9yrs

Average management tenure


CEO

Jaap Stuut (50 yo)

3.08yrs

Tenure

UK£284,000

Compensation

Mr. Jaap Stuut has been the Chief Executive Officer of Immunodiagnostic Systems Holdings PLC since November 1, 2017. Mr. Stuut has been with the Immunodiagnostic Systems Holdings PLC since 2013 and was pre...


CEO Compensation Analysis

Compensation vs Market: Jaap's total compensation ($USD382.59K) is about average for companies of similar size in the UK market ($USD340.62K).

Compensation vs Earnings: Jaap's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jaap Stuut
CEO & Director3.08yrsUK£284.00k0.026%
£ 16.1k
Paul Martin
Group Finance Director4.92yrsUK£250.00k0.078%
£ 48.1k
Sander Gentil
Head of Marketing & Communicationsno datano data0.0035%
£ 2.1k
Nicola Mitton
Group HR Directorno datano datano data
Ed Coombes
Head Of Business Development - Instrumentationno datano datano data
Rudolf Schemer
CEO of GeschTMaftsfuhrer at IDS GmbH Frankfurt & Country Manager of Germany Region13.75yrsno datano data

4.9yrs

Average Tenure

50yo

Average Age

Experienced Management: IDH's management team is considered experienced (4.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jaap Stuut
CEO & Director3.08yrsUK£284.00k0.026%
£ 16.1k
Paul Martin
Group Finance Director4.92yrsUK£250.00k0.078%
£ 48.1k
Burkhard Wittek
Non-Executive Chairman5.92yrsUK£60.00k0.15%
£ 94.3k
Peter Kaspar
Independent Non-Executive Director5.08yrsUK£30.00k0.063%
£ 38.9k
Peter Williamson
Independent Non-Executive Director5.5yrsUK£30.00k0.16%
£ 96.8k

5.1yrs

Average Tenure

54yo

Average Age

Experienced Board: IDH's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Immunodiagnostic Systems Holdings PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immunodiagnostic Systems Holdings PLC
  • Ticker: IDH
  • Exchange: AIM
  • Founded: 1977
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£61.886m
  • Shares outstanding: 28.78m
  • Website: https://www.idsplc.com

Number of Employees


Location

  • Immunodiagnostic Systems Holdings PLC
  • Boldon Business Park
  • 10 Didcot Way
  • Boldon
  • Tyne and Wear
  • NE35 9PD
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IDHAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2004
LWXDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2004

Biography

Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internatio...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/12/04 20:21
End of Day Share Price2020/12/04 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.